Apr 17 |
Acrivon Therapeutics files to sell 15.29M shares of common stock for holders
|
Apr 17 |
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
|
Apr 10 |
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resis...
|
Apr 9 |
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
|
Apr 9 |
Dow Dips 150 Points; Laser Photonics Shares Spike Higher
|
Apr 9 |
Acrivon Therapeutics stock surges on $130M private placement financing
|
Apr 9 |
Acrivon Therapeutics Announces $130 Million Private Placement Financing
|
Mar 30 |
Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ...
|